Arhalofenate
Based on 1 publication(s) in Google Scholar
Arhalofenate (MBX 102) is a selective partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ, used for the treatment of type 2 diabetes.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.13%
- No. CAS: 24136-23-0
- Fòrmula: C19H17ClF3NO4
- Peso molecular:415.79
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-13956
PioglitazonePPARγ Agonist -
HY-17386
RosiglitazonePPARγ Agonist -
HY-17618
PemafibratePPARα Agonist -
HY-50935
TroglitazonePPARγ Agonist -
HY-B0258
GemfibrozilCytochrome P450 Inhibitor -
HY-14600
Rosiglitazone maleatePPARγ Activator -
HY-17386R
Rosiglitazone (Standard)PPARγ Agonist -
HY-B0258R
Gemfibrozil (Standard) -
HY-16578
GW9662PPARγ Antagonist -
HY-16995
Pirinixic acidPPAR Agonist -
HY-15372
GW6471PPARα Antagonist -
HY-13956R
Pioglitazone (Standard)PPARγ Agonist
Publications Citing Use of MedChemExpress (MCE) Arhalofenate
More
Actividad biológica
Descripciòn
IC50 & Target
|
PPAR-γ |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | EC50 |
12 μM
Compound: 5, MBX-102
|
Activity at human PPARgamma transfected in HEK293 cells assessed as transactivation activity by luciferase reporter gene assay
Activity at human PPARgamma transfected in HEK293 cells assessed as transactivation activity by luciferase reporter gene assay
|
[PMID: 25734377] |
In Vitro
Arhalofenate (MBX 102) is a prodrug ester, that is rapidly and completely modified in vivo by non-specific serum esterases to the mature free acid form Arhalofenate (MBX 102) acid. Arhalofenate (MBX 102) shows a dose-dependent activation of mouse GAL4-PPAR-γ with EC50s of appr 12 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 24136-23-0
-
Appearance Solid
-
Peso molecular 415.79
-
Fòrmula C19H17ClF3NO4
-
Color Off-white to light yellow
-
SMILES
O=C(OCCNC(C)=O)[C@@H](C1=CC=C(Cl)C=C1)OC2=CC=CC(C(F)(F)F)=C2
-
Synonyms
MBX 102; JNJ 39659100
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Drug Dev Res
The mechanism of Arhalofenate in alleviating hyperuricemia-Activating PPARγ thereby reducing caspase-1 activity. [Abstract]2020 Nov;81(7):859-866. PMID: 32506648
Pureza y Documentación
-
Ficha de datos (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Gregoire FM, et al. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009 Jul;23(7):975-88. [Content Brief]
[2]. Chandalia A, et al. MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation. PPAR Res. 2009;2009:706852. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Arhalofenate Related Classifications
HY-14831 Related Classifications
Powered by Bioz